C M Bidwell & Associates LTD Ligand Pharmaceuticals Inc Transaction History

C M Bidwell & Associates LTD

  • $162 Million
  • Q3 2024

A detailed history of C M Bidwell & Associates LTD transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, C M Bidwell & Associates LTD holds 52 shares of LGND stock, worth $6,361. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52
Previous 52 -0.0%
Holding current value
$6,361
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$68.64 - $89.2 $1,510 - $1,962
22 Added 73.33%
52 $3,000
Q3 2023

Nov 13, 2023
SELL
$58.86 - $72.67 $73,045 - $90,183
-1,241 Reduced 97.64%
30 $1,000
Q2 2023

Aug 11, 2023
BUY
$69.53 - $79.33 $87,329 - $99,638
1,256 Added 8373.33%
1,271 $91,000
Q1 2023

May 11, 2023
BUY
$65.67 - $77.08 $985 - $1,156
15 New
15 $1,000
Q4 2020

Feb 16, 2021
SELL
$80.55 - $106.05 $55,821 - $73,492
-693 Closed
0 $0
Q3 2020

Nov 13, 2020
SELL
$89.56 - $126.72 $177,060 - $250,525
-1,977 Reduced 74.04%
693 $66,000
Q2 2020

Aug 14, 2020
BUY
$68.28 - $123.65 $182,307 - $330,145
2,670 New
2,670 $299,000
Q2 2019

Aug 07, 2019
SELL
$107.38 - $129.34 $117,581 - $141,627
-1,095 Closed
0 $0
Q1 2019

May 15, 2019
BUY
$105.93 - $142.47 $115,993 - $156,004
1,095 New
1,095 $138,000
Q4 2018

Feb 14, 2019
SELL
$128.36 - $272.13 $32,731 - $69,393
-255 Closed
0 $0
Q3 2018

Nov 13, 2018
SELL
$211.18 - $274.49 $1,055 - $1,372
-5 Reduced 1.92%
255 $70,000
Q1 2018

May 11, 2018
BUY
$138.63 - $182.62 $36,043 - $47,481
260 New
260 $43,000

Others Institutions Holding LGND

# of Institutions
257
Shares Held
18.2M
Call Options Held
26.8K
Put Options Held
9.3K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $2.07B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track C M Bidwell & Associates LTD Portfolio

Follow C M Bidwell & Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of C M Bidwell & Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on C M Bidwell & Associates LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email